This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEB2C0AG_M.jpg
Engine Capital, which owns about a 3% stake in 2seventy bio, said the company should exclusively focus on its blood cancer therapy Abecma, and explore ways to “immediately cease or monetize all development programs”.
2seventy bio did not immediately respond to a request for comment.
